<DOC>
	<DOCNO>NCT02100852</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness TGR-1202 combination obinutuzumab ( Gazyva ) chlorambucil patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>TGR-1202 , PI3K Delta Inhibitor , Combination With Obinutuzumab Chlorambucil Patients With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Confirmed Chronic Lymphocytic Leukemia ( CLL ) Eastern Cooperative Oncology Group ( ECOG ) score 0 2 Ability swallow oral medication Known hepatitis B virus , hepatitis C virus HIV infection Primary central nervous system lymphoma know intracranial involvement Autologous hematologic stem cell transplant within 3 month study entry Allogeneic hematologic stem cell transplant within 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>